ARTGEN THERAPEUTICS
Artgen is developing novel non-viral gene therapies for treatment of vascular diseases. Their lead product candidate, ART-101, is a DNA plasmid designed to stimulate angiogenesis with the first indication directed for Peripheral Artery Disease (PAD). ART-101 expresses Vascular Endothelial Growth Factor (VEGF), one of the key regulators of angiogenesis. Artgen's platform technology has the potential for treatment of other vascular diseases.
Similar Organizations
Anagin
Anagin is developing first-in-class therapies for treating neuropsychiatric diseases.
BELX BioPharma
develop botanical new drugs for treatments of tumors, chronic liver diseases and cancers
Bikam
Bikam developing novel therapies for diseases of the eye.